Epigenetic reprogramming underlies efficacy of DNA demethylation therapy in osteosarcomas

Area of Science:

• Oncology
• Epigenetics
• Molecular Biology

Background:

• Osteosarcoma (OS) with metastasis or recurrence has a poor prognosis.
• The therapeutic mechanisms of DNA demethylation therapy for OS remain unclear.
• Epigenetic alterations, particularly DNA methylation, play a role in OS development.

Purpose of the Study:

• To elucidate the mechanism underlying the therapeutic efficacy of epigenetic therapy in osteosarcoma.
• To investigate the effects of DNA demethylation on OS cell growth and gene expression.

Main Methods:

• Treatment of four OS cell lines and two OS xenografts with 5-aza-2 -deoxycytidine (5-aza-dC).
• Genome-wide DNA methylation analysis of primary OS samples.
• Expression microarray screening of OS cell lines after 5-aza-dC treatment.

Main Results:

• 5-aza-dC treatment significantly suppressed OS cell growth in vitro and in vivo.
• Aberrant DNA methylation, particularly in CpG islands, was observed in a subset of primary OS.
• Genes involved in skeletal system morphogenesis were among those aberrantly methylated.
• 5-aza-dC treatment re-activated multiple tumor-suppressor and osteo/chondrogenesis-related genes.

Conclusions:

• DNA demethylation therapy, via 5-aza-dC, demonstrates therapeutic potential in osteosarcoma.
• The efficacy is attributed to the epigenetic reprogramming and re-activation of silenced tumor-suppressor and differentiation-related genes.
• Targeting DNA methylation represents a promising strategy for treating osteosarcoma, especially in recurrent or metastatic cases.